Tritace 2.5 mg 14 tablets

Tritace 2.5 mg 14 tablets

Composition:
Ramipril 2.5 mg

Pharmacological properties:
Tritace is an antihypertensive drug, an ACE inhibitor. Ramiprilat, an active metabolite of ramipril, is a long-acting ACE inhibitor. In blood plasma and tissues, this enzyme catalyzes the conversion of angiotensin I to angiotensin II (an active vasoconstrictor) and the breakdown of the active vasodilator bradykinin. A decrease in the formation of angiotensin II and an increase in the activity of bradykinin leads to vasodilation and contributes to the cardioprotective and endothelial-protective effect of ramipril. Angiotensin II stimulates the release of aldosterone, therefore ramipril causes a decrease in aldosterone secretion. Taking ramipril leads to a significant decrease in total peripheral vascular resistance, generally without causing changes in renal blood flow and glomerular filtration rate. Taking ramipril causes a decrease in blood pressure both in the supine and standing positions without a compensatory increase in heart rate. The hypotensive effect begins 1-2 hours after taking a single dose of the drug orally and lasts for 24 hours. The maximum antihypertensive effect of Tritace usually develops by the 3rd-4th week of continuous use of the drug and is maintained for a long time. Sudden cessation of the drug does not lead to a rapid and significant increase in blood pressure. The use of the drug reduces mortality (including sudden death), the risk of severe heart failure, and reduces the number of hospitalizations of patients with clinical signs of chronic heart failure after acute myocardial infarction. In patients with diabetic and non-diabetic clinically expressed nephropathy, the drug reduces the rate of progression of renal failure, and at the preclinical stage of diabetic and non-diabetic nephropathy, ramipril reduces albuminuria. The drug has a beneficial effect on carbohydrate metabolism and lipid profile, causing a decrease in severe myocardial hypertrophy and vascular wall.

Indications for use:
• Arterial hypertension (high blood pressure)
• Chronic heart failure
• Post-infarction condition (as part of complex therapy)
• Prevention of heart attack and stroke in patients at high risk
• Diabetic nephropathy (kidney protection).

Method of administration and dosage:
The dose is selected by the doctor individually.
The initial dose of Tritace is usually 2.5 mg, taken once a day, on an empty stomach and washed down with water. Later, if the effect is insufficient, the dose of Tritace is gradually increased every 2-3 weeks and also prescribed for a single dose during the day. The maximum daily dose of Tritace is 10 mg, and the maintenance dose is usually 2.5-5 mg. In chronic heart failure, the recommended initial dose is 1.25 mg/day. Then the dose can be increased (over the course of 1 to 2 weeks). If the daily dose of Tritace is 2.5 mg or more, then Tritace can be taken in 1 or 2 doses.